Dexibuprofen
Generic name
Dexibuprofen
Brand name
ATC Code
M01AE14
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Keine Daten verfügbar
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Pain, fever and inflammation, JIA |
|---|
|
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Consider whether the application of NSAIDs is justified. If ibuprofen is still prescribed and the patient belongs to a high-risk group: Check renal function before and within 1 week of starting ibuprofen treatment.GFR 30-50 ml/min/1.73 m2
Consider whether the application of NSAIDs is justified. If ibuprofen is still prescribed and the patient belongs to a high-risk group: Check renal function before and within 1 week of starting ibuprofen treatment.GFR 10-30 ml/min/1.73 m2
Consider whether the application of NSAIDs is justified. If ibuprofen is still prescribed and the patient belongs to a high-risk group: Check renal function before and within 1 week of starting ibuprofen treatment.GFR < 10 ml/min/1.73 m2
General information can not be given.Clinical consequences
Risk factors include heart failure, liver cirrhosis, nephrotic syndrome, chronic kidney disease, dehydration-promoting factors (eg heat), the use of nephrotoxic drugs such as diuretics or RAAS inhibitors.
NSAIDs (including COX-2 inhibitors) may cause acute renal failure due to decreased renal perfusion (due to hypovolemia). Normally, an excessive decrease in renal perfusion is prevented by increased prostaglandin synthesis in the kidneys. NSAIDs interfere with this compensation mechanism. Reduced renal perfusion results in retention of water and salt, leading to the development or worsening of hypertension and heart failure.
Patients on dialysis
Hemodialysis / continuous veno-venous hemodialysis / hemofiltration:
• Kidney residual function (urine production) present: Do not use to maintain residual kidney function.
• Kidney residual function (urine production) NOT present: Avoidance of the application is not required.
Patients undergoing dialysis have a higher risk of bleeding, probably due to abnormal platelet function. The risk of bleeding can be further increased by the use of a low molecular weight heparin to prevent coagulation in the extracorporeal circulation at the beginning of hemodialysis.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Transient episodes of apnea ocurred in infants after taking large amounts of drug [SmPC Seractil].
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Acetic acid derivatives and related substances | ||
|---|---|---|
| M01AB05 | ||
| M01AB01 | ||
| Oxicams | ||
|---|---|---|
| M01AC01 | ||
| Propionic acid derivatives | ||
|---|---|---|
| M01AE01 | ||
| M01AE02 | ||
| Fenamates | ||
|---|---|---|
| M01AG01 | ||
| Coxibs | ||
|---|---|---|
| M01AH01 | ||
Reference
- Gebro, SmPC Seractil 200 mg Ftbl. (1-20001), 07/2015
Changes
Therapeutic Drug Monitoring
Overdose
